

BGI SENTIS™ HRD Score Testing

sentis™
HRD Score Testing

Introduction

The status of Homologous Recombination Deficiency (HRD) is one of the key factors for the evaluation of PARP inhibitor efficacy, which will help clinicians to determine whether the PARP inhibitor drugs would be effective for patients. BGI SENTIS™ HRD Score Testing use a custom SNP array to detect the variations and evaluate comprehensive genomic instability status using extracted DNA from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens.

Application Population

Ovarian Cancer Patients (Breast cancer, prostate cancer and pancreatic cancer are in developing)

Sample Type

Tumor Tissue (Tumor cell content ≥30%)

More than 50% of ovarian cancer patients are HRD-positive and they will be benefit from PARP inhibitors significantly.



PAOLA 1 - Clinical trial data indicates that: HRD-positive patients were significantly benefit from olaparib combined with bevacizumab while HRD score-negative patients were not. [1]



PRIMA - Clinical trial data indicates that: PFS benefit was similar in two subgroups of HRD-positive patients (regardless of BRCA mutation status).

In HRD-negative patients, the risk of disease progression or death was reduced by 32% with niraparib, but PFS was only prolonged by 2.7 months. [2]



[1] Ray-Coquard I et al. Presentation LBA2_PR presented at ESMO Annual Conference 2019, 27 September - 1 October, Barcelona, Spain
[2] A. González Martín Presented at ESMO2019

Compared with BCRA1/2 gene testing, HRD Score testing can screen out 36.62% more population that will be benefit from PARP inhibitors.



*BGI in-house data, based on the test result of 2152 ovarian cancer samples.

BGI HRD Score Testing Solutions

Technology Transfer Service

Reagent Kit

Equipment

Bioinformatic Analysis and
Interpretation through BGI Online

Technical Support

Lab Design, On-site Training, Software Upgrade,
Other Technical Support

Offshore Service Solution

Product Category	Product Name	Product Code	TAT (Days)	Sample Received by
SENTIS™ HRD	SENTIS™ Homologous Recombination Deficiency (HRD) Test (HRD Score)	HW2161	14	BGI Hong Kong Central Lab

Two Upgrading Products Will be Launched Soon

HRD Plus:

Testing content: (HRD Score) + (tBRCA1/2 or g+sBRCA1/2)

HRD Pro:

Testing content: (HRD Score) + (homologous recombination pathways and genetically related genes) + (Germline BRCA1/2 large fragment rearrangement)

www.bgi.com/global/
info@bgi.com

Published September 2022.